Podcasts about BCG

Space isn't just for rockets and research anymore. Satellite technology drives precision navigation, automation, and connectivity—quietly powering everything from farming to finance. Troy Thomas, BCG's global lead for space business, explains why CEOs need a deliberate space strategy to stay ahead of disruption and unlock new growth. Learn More: Troy Thomas: https://on.bcg.com/4qhq5ea BCG on the Space Sector: https://on.bcg.com/4hohjqS Space Services Are the Next Frontier for Industrial Companies: https://on.bcg.com/47zs3za GAIA: A Foundation Model for Operational Atmospheric Dynamics: https://arxiv.org/abs/2505.18179 GAIA Foundation Model is available for download: https://huggingface.co/bcg-usra-nasa-gaia Chapters 00:00- 01:16 Introduction/Troy's ‘So What' 01:17-01:57 What would a day look like without space? 01:58-04:02 How big is the space industry? 04:03-06:01 The three pillars of space 06:02-08:05 What pillar is the most significant for growth? 08:06-10:40 What can space tech really do for a company? 10:41-12:50 Does every company need a space strategy? 12:51-14:22 What does a good space strategy look like? 14:23-15:52 How do you manage risks? 15:53-16:55 Why would you own your own space assets? 16:56-19:13 Is there enough space in space? 19:14-20:33 BCG's work with NASA 20:34-22:21 How will space impact the future? 22:22-23:04 Troy's ‘Now What' 23:05-23:18 Outro This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.---TIMESTAMPS00:00 - Introduction05:09 - Challenges and Strategies in Treatment10:55 - Bladder Sparing Therapies21:41 - Practical Tips for Therapy Administration30:39 - Challenges and Considerations in Reinduction37:05 - Clinical Trials and Future Directions44:11 - Counseling Patients on Treatment Options57:36 - Concluding Thoughts and Future Outlook---RESOURCESCORE-008 Clinical Trial https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147Legend Clinical Trial:https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802CISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

Send us a textTauseef spent a decade at BCG, rising to Principal and leading AI transformation and go-to-market strategy projects across the globe. In this convo, he breaks down exactly how to stand out in today's competitive recruiting landscape.You'll learn:How Tauseef secured offers from BCG, McKinsey, and moreWhat separates candidates who land offers from those who don'tThe X factor that will make you unforgettable in interviewsHow to design your consulting experience once you're in the firmTauseef also shares how networking helped him shape his entire BCG career – including how he had his pick of projects for four straight years.Whether you're preparing for interviews, trying to land a referral, or curious about what life inside MBB is really like, this episode is packed with insights from someone who's lived it all.Additional Resources:Work directly with Tauseef on case and behavioral prepJoin Black Belt for structured prep that covers networking, resumes, and interviewsBook a free 15-minute call with Katie for personalized guidance on which program fits you bestPractice live cases on YouTubeListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe conversation covers initial patient consultations, discussing diagnoses, personalized treatment options such as BCG, gemcitabine, clinical trials, and managing side effects. The experts emphasize the importance of clear communication, understanding patient preferences, and tailoring approaches to enhance the patient's quality of life. They also explore insights from recent studies like the CISTO trial and highlight novel research directions.---TIMESTAMPS00:00 - Introduction04:28 - Counseling Patients on Diagnostic Findings12:03 - Symptom Management and Patient Care19:30 - Post-Procedure Care and Counseling28:50 - Recovery After TURBT: Medications and Patient Care44:16 - The Impact of Radical Cystectomy on Quality of Life49:15 - Final Thoughts and Future Directions in Bladder Cancer Care---RESOURCESNIMBUS Studyhttps://pubmed.ncbi.nlm.nih.gov/32446864/

Send us a textIn this case example, former McKinsey consultant Ravi Chandra leads a profitability case in Greece's cheese industry – with a real candidate tackling it live before an audience. Listen as Ravi tests structuring, math, and communication under pressure, while offering real-time coaching and feedback.You'll learn how to:Build clear, MECE frameworksTackle profitability casesTurn math into actionable insightsAvoid common pitfallsWhether you're prepping for McKinsey, BCG, or Bain, this episode gives you a front-row seat to what top firms expect.Work with Ravi:Book a 1:1 coaching session with RaviJoin the Black Belt case prep program for 1:1 coaching with Ravi Connect on LinkedInAdditional Resources:Subscribe on YouTube for more live casesUnlock your next consulting job – create a free profile on the Management Consulted Job BoardPractice McKinsey-style math with MC's free Math DrillsListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Hot take: I loved working in a Skilled Nursing Facility. Skilled nursing facilities are one of the highest paid settings for occupational therapy professionals. And about one-fifth of us work in one. But, work in one can have a bad rap. In today's intro to SNF OT course, we'll walk through the common challenges, and immense opportunities of working in a SNF. We'll cover the specific things you need to know, from payment models to common assessments. And, we'll paint a picture of how you as an OT can really be a driver of culture and care in this unique and important setting.We'll be joined by Trent Brown, MOT, OTR/L, ATP, CGCP, CFPS, BCG, a practicing occupational therapist, who is also a part of the Department of Health and Human Services (DHHS) as an assistant office director with a focus on developing and operating quality improvement programs, particularly in SNFs.Support the show

In today's episode, we had the pleasure of speaking with Joseph Jacob, MD, MCR, about the FDA approval of the gemcitabine intravesical system (formerly TAR-200; Inlexzo)​ for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer. Dr Jacob is an associate professor of urology and the director of Urologic Oncology in the Department of Urology at State University of New York Upstate Medical University in Syracuse. In our exclusive interview, Dr Jacob discussed the significance of this approval, key efficacy findings from the pivotal phase 2b SunRISe-1 trial (NCT04640623), and the TAR-200 administration procedure, which he describes as straightforward for practitioners and convenient for patients.

https://www.big-fintech.com/the-great-wealth-transfer-great-inheritance-drain/John and Glen speak with Defense Credit Union Council CEO Tony Hernandez about his organization's rapidly increasing visibility and how the armed forces' impact on the credit union movement extends well beyond the expected nameplates. Also- the shutdown creates new complexities for earned wage access, Bitcoin breaks the $125K barrier, and plenty of bingo card calls.       Links related to this episode:   The Defense Credit Union Council (including government shutdown resources): https://www.dcuc.org/     The CU Daily's recent interview with DCUC CEO Tony Hernandez: https://thecudaily.com/the-defense-cu-council-goes-on-the-offense-echoes-a-page-from-cu-history/    Create your own 2025 BIGGo card: https://bingobaker.com/#67a12342928998c6    Our recent interview with earned wage access provider Veep Software (among other startups): https://www.big-fintech.com/the-great-wealth-transfer-great-inheritance-drain/    Our April blog about the Executive Order “eliminating” government paper checks: https://www.big-fintech.com/executive-order-to-eliminate-checks-isnt-worth-the-paper-its-printed-on/     BCG's 2025 Global Payments Report: https://www.bcg.com/publications/2025/global-payments-transformation-amid-instability    McKinsey's 2025 Global Payments Report: https://www.mckinsey.com/industries/financial-services/our-insights/global-payments-report    Join us for our next CU Town Hall- Wednesday October 15 at 3pm ET/Noon PT- for a live and lively interactive conversation tackling the major issues facing credit unions today. Quantum computing will be among the topics discussed this session, given HSBC's announced financial services breakthrough. The Town Hall is free to attend, but advance registration is required:  https://www.cutownhall.com/   Follow us on LinkedIn:  https://www.linkedin.com/company/best-innovation-group/   https://www.linkedin.com/in/jbfintech/  https://www.linkedin.com/in/glensarvady/

What happens when a group of friends gathering at Starbucks on Sundays to experiment with ChatGPT evolves into a global movement spanning more than 40 cities?That's the journey of Build Club, and its founder Annie Liao has some compelling insights about what it takes to actually make AI adoption work—not just in theory, but in practice.Annie, who recently raised over $1.7 million and relocated to San Francisco, has a front-row seat to how AI is reshaping work. From her early days in data science at Westpac to strategy consulting at BCG and venture capital, she's now solving what she calls the "AI adoption problem" that enterprises are struggling with worldwide.In this episode, you'll hear:Why Annie's "AI Champions" approach has been Build Club's most successful way of helping companies embrace AI How she struck partnership deals with big names like Nvidia and LovableAnnie's prediction we're all likely to have agents working overnight on our behalf and what that meansThe AI tools Annie uses in her daily workflow, andWhat makes San Francisco's AI ecosystem fundamentally different from Australia'sFrom her vantage point in the Bay Area, Annie shares what excites her most about seeing people use AI for the first time, why there might be too many no-code tools flooding the market, and the practical steps anyone can take to position themselves for what's coming next.Enjoy this episode with the indomitable Annie Liao. Useful links:Build Club websiteAnnie Liao on LinkedIn Hosted on Acast. See acast.com/privacy for more information.

Send us a textWhat if you didn't go to a target school? What if you're an international student who needs sponsorship? Does that mean MBB is out of reach?Michael Liu is living proof that the answer is no. In this episode, Japheth sits down with Michael, an undergraduate student from Taiwan who defied the odds to land a BCG internship.Michael shares the exact steps he took to break in, including:How he built a powerful networking strategyOvercame the sponsorship hurdlePrepared for both case and behavioral interviewsHis story is full of practical insights and encouragement you can apply to your own recruiting journey — whether you're at a non-target school, navigating visa questions, or just looking for that extra edge.Additional Resources:Join Black Belt, a structured case prep program that helps candidates land MBB offersPractice case interviews live or on-demand with real case prompts on YouTubeSee a list of consulting firms that sponsor international candidatesPartner Links:Stax is hiring! See open roles and requirementsGet real consulting experience from your bedroom in the November 2025 Strategy Sprint project; $200 off expires October 3 Listen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

In this episode of FP&A Unlocked, host Paul Barnhurst is joined by Alex Fabry, the founder of KFA, an advisory firm focused on scaling businesses.. Alex takes us through his journey from FP&A to private equity, sharing his valuable experiences working at firms like Saber, BCG, and Charles Bank Capital Partners. Their conversation explores how FP&A can serve as a stepping stone to leadership and investment roles, and the key skills that helped Alex succeed in both corporate finance and private equity.Alex Fabry is the founder and managing partner of KFA, a private investment and advisory firm focused on growing and scaling businesses in Saint Louis. Before founding KFA, Alex started his career in FP&A roles at Saber, where he supported multi-billion dollar business units, managed complex budgets, and played a pivotal role in the $1.2 billion sale of Active Network to Global Payments. Alex also has experience as a Vice President at Charles Bank Capital Partners. He holds an MBA from the Kellogg School of Management at Northwestern University.Expect to Learn:How FP&A provides a solid foundation for leadership and private equity operator roles.The significance of automation in improving FP&A efficiency and enabling more strategic analysis.Why private equity and FP&A require different skill sets but can work in tandem to drive business growth.Key skills FP&A professionals need to transition into private equity.The value of relationships and trust in both FP&A and private equity environments.Here are a few quotes from the episode:“The real value of FP&A is in helping businesses make decisions, not just report numbers.” - Alex Fabry“Being a business partner looks different depending on the business—it's about them, not you." - Alex FabryAlex shared thoughtful and practical insights into the evolving role of FP&A in driving business success and the transition to private equity. He highlighted the importance of automation and strategic analysis in improving financial operations, the value of building strong business relationships, and how FP&A professionals can leverage their skills to thrive in the private equity space. Alex's journey serves as a valuable playbook for those looking to navigate the complexities of both FP&A and private equity, emphasizing the need for adaptability, operational efficiency, and a keen understanding of the bigger business picture.Campfire: AI-First ERP:Campfire is the AI-first ERP that powers next-gen finance and accounting teams. With integrated solutions for general ledger, revenue automation, close management, and more, all in one unified platform.Explore Campfire today: https://campfire.ai/?utm_source=fpaguy_podcast&utm_medium=podcast&utm_campaign=100225_fpaguyFollow Alex:LinkedIn - https://www.linkedin.com/in/alex-fabry/Earn Your CPE Credit For CPE credit, please go to earmarkcpe.com, listen to the episode, download the app, answer a few questions, and earn your CPE certification. To earn education credits for the FP&A Certificate, take the quiz on Earmark and contact Paul Barnhurst for further details.In Today's Episode[02:27] - Alex's Background[03:50] - What Makes Great FP&A?[14:03] - The Three Key Questions in Finance[18:38] - Private Equity...

Send us a textWant to land a consulting role in the Middle East? This episode breaks down the 2025 recruiting landscape and what it takes to succeed in this unique region.We cover:How the Middle East consulting market is shaped by nationalization, expat hiring, and cultural dynamics3 recruiting power moves you can use right nowTop schools, firms, and timing to keep on your radarFor the full playbook, download Management Consulted's Middle East Consulting Recruitment Roadmap – free.Inside, you'll find firm-by-firm insights, hiring timelines, and proven strategies to land an offer.Additional Resources:Join Black Belt, an expert prep program that's helped candidates break into McKinsey, Bain, BCG, and more across the regionFollow along on YouTubeGet real consulting experience from your bedroom in the November 2025 Strategy Sprint project; $200 off expires October 3 Listen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Welcome back to the Alt Goes Mainstream podcast.Today's episode provides a fascinating window into the world of private equity value creation and how AI can help transform both portfolio company and investment firm processes and operations to create value.We sat down in New York with Hg Partner and Head of Value Creation Chris Kindt to dive into how he spearheaded the growth of the firm's in-house value creation efforts and has built a high-performing team to meet the evolving needs of portfolio companies.Chris brings 15 years of experience in architecting and driving value creation to bear, with 11 years of experience at Hg and another 8 years as a consultant at BCG and Parthenon.Chris and his team are responsible for driving value across a portfolio of 55 companies that represents over $180B in enterprise value and would represent the second largest software company in Europe after SAP if it were a conglomerate.Chris and I had a thought-provoking discussion about value creation and the impact of AI on investing and operating companies. We discussed:How to build a high-performing value creation team.Where value creation has the biggest impact.How AI is transforming investment processes.How Hg has become an “AI-first” investment firm.Where AI will have the most impact in a company today and why agentic AI is transforming certain roles and processes within companies.How professionals can generate the most leverage from utilizing AI – without having cognitive decline.Why prompting and prompt engineering is so critical in the age of AI (and how you can use your weekends to perfect prompt engineering).How a management team can buy into AI and why the current time period represents an interesting opportunity for incumbents, particularly for those building mission-critical enterprise software.Thanks Chris for sharing your expertise and wisdom on company building and AI. We hope you enjoy.Note: this episode was filmed in August 2025.A word from AGM podcast sponsor, Ultimus Fund SolutionsThis episode of Alt Goes Mainstream is brought to you by Ultimus Fund Solutions, a leading full-service fund administrator for asset managers in private and public markets. As private markets continue to move into the mainstream, the industry requires infrastructure solutions that help funds and investors keep pace. In an increasingly sophisticated financial marketplace, investment managers must navigate a growing array of challenges: elaborate fund structures, specialized strategies, evolving compliance requirements, a growing need for sophisticated reporting, and intensifying demands for transparency.To assist with these challenging opportunities, more and more fund sponsors and asset managers are turning to Ultimus, a leading service provider that blends high tech and high touch in unique and customized fund administration and middle office solutions for a diverse and growing universe of over 450 clients and 1,800 funds, representing $500 billion assets under administration, all handled by a team of over 1,000 professionals. Ultimus offers a wide range of capabilities across registered funds, private funds and public plans, as well as outsourced middle office services. Delivering operational excellence, Ultimus helps firms manage the ever-changing regulatory environment while meeting the needs of their institutional and retail investors. Ultimus provides comprehensive operational support and fund governance services to help managers successfully launch retail alternative products.Visit www.ultimusfundsolutions.com to learn more about Ultimus' technology enhanced services and solutions or contact Ultimus Executive Vice President of Business Development Gary Harris on email at gharris@ultimusfundsolutions.com.We thank Ultimus for their support of alts going mainstream.Show Notes00:00 Message from our Sponsor, Ultimus01:18 Welcome to the Alt Goes Mainstream Podcast02:10 Guest Introduction: Chris Kindt03:58 Chris Kindt's Background and Journey05:43 Value Creation at Hg06:55 Pre-Investment and Diligence Process07:44 Management Team Dynamics08:40 Common Value Creation Interventions11:14 Building a Cross-Functional Team12:31 Scaling the Value Creation Team15:40 Measuring Value Creation Impact17:49 Investment Philosophy: Inch Wide, Mile Deep19:28 Partnerships with Management Teams20:03 Embedding AI in Value Creation20:24 Internal vs External AI Applications21:47 AI First Culture22:18 Effective AI Utilization24:04 Prompt Engineering and Whispering26:25 Choosing the Right AI Models26:50 AI Models: Strengths and Weaknesses27:42 Transformative Impact of AI28:21 Skills Needed in the AI Era28:26 AI's Role in Investment Firms28:55 Core Insights and Judgements29:04 The Core Skillset and Efficiency29:12 Philosophical Questions on AI and Talent Development30:18 Building Grit in the Age of AI31:12 Maintaining Discipline with AI32:08 AI as a Value Creation Lever32:35 Operational Efficiency and Copilots33:43 Emergence of Reasoning Models and Agentic Frameworks34:31 10x Efficiency in Engineering36:24 Challenges in Implementing AI37:16 AI Immersion Strategy Days39:52 Organizational Agility and AI42:15 AI's Impact on Investment Strategies43:26 AI in Mergers and Acquisitions45:29 The Importance of Proprietary Data47:12 AI Fatigue and Disillusionment48:07 Building AI Products and Agentic Products48:58 Hg's Internal AI Incubator49:59 The Next Wave of AI51:19 Voice and Multimodality in AI51:55 Globalization and Internationalization of AI53:35 Overestimating and Underestimating AI's Impact54:54 The Competitive Landscape of AI55:42 The Future of Value Creation with AI56:23 Conclusion and Final ThoughtsEditing and post-production work for this episode was provided by The Podcast Consultant.

Martin Reeves has spent decades advising CEOs on how to think about strategy. As head of BCG's Henderson Institute, he has built a career challenging leaders to balance efficiency with imagination and to prepare for the next disruptive shift.In this conversation, Martin tells Henrik and Jeremy why AI alone will not give companies an edge and might even strip them of advantage. He unpacks the “two jobs of business”: playing the current game better than anyone else while simultaneously asking what the next game will be. He argues that AI only sharpens this paradox, forcing leaders to think faster, experiment more, and draw on human imagination in new ways.The discussion covers the risks of over-optimization, the future of consulting, and the paradoxes of AI adoption. Along the way, Reeves explains how AI can accelerate exploration, why framing the right questions is the strategist's most important job, and why times of disruption are when number twos become number ones or disappear altogether.Key Takeaways: Strategy is the double gameLong-term success means playing today's game efficiently while also inventing tomorrow's. Henrik and Jeremy stress how rare it is for leaders to do both, yet this is exactly what AI demands.AI efficiency without imagination is a trapAdopting the same tools as competitors drives efficiency but commoditizes advantage. The hosts underline that imagination and unique use are what create real differentiation.The strategist's edge is asking the right questionMartin highlights that strategy starts with framing the real question. Henrik and Jeremy note that questioning and cognitive diversity are crucial in the AI era.Disruption reshuffles winners and losersTimes of change are when number twos become number ones and leaders disappear. The wrap-up emphasizes the urgency of experimenting and adapting now.Human imagination stays essentialAI can accelerate exploration, but creativity, ethics, and originality remain uniquely human — and decisive for future leadership.LinkedIn: Martin Reeves | LinkedInBCG Henderson Institute: Home - BCG Henderson InstituteMartins books: The Imagination Machine // Like: The Button That Changed the World00:00 Intro: Two Jobs in Strategy, Today's Game and Tomorrow's Game01:33 Martin Reeves and the Henderson Institute04:02 Defining Strategy in the AI Era05:12 AI and Human Imagination09:20 Efficiency vs. Competitive Advantage13:18 Organizational Design for the Future23:09 The Paradox of Imagination in Business33:02 Harnessing Serendipity for Innovation35:18 Devil's Advocacy and Meeting Optimization36:51 Where AI Helps and Hurts Organizations38:16 The Limits of AI Training Data42:56 How Martin Uses AI Day to Day47:09 What's the Next Game for Consulting53:15 Final Reflections

A CMO Confidential Interview with Dwight Hutchins, Senior Managing Director of Boston Consulting Group (BCG) and a Northwestern Adjunct Professor, previously Managing Director at Accenture focused on Consumer Products, Health Care and Public Service. Dwight shares his thinking on why marketers should be prepared to reduce expenses and shift resources into a re-imagined future versus incrementally evolving spend and structure. Key topics include: his belief that the complexity of marketing has resulted in many instances of wasted spending; the importance of "unaided first brand response;" why it's important to be "ahead of the expense reduction game;" and how to focus on working versus non-working dollars. Tune in to hear how about reducing $1B in spend to fund new initiatives and a "wild west" story about a battery on-pack promotion.The Fine Art of Reducing Marketing Expense in an AI WorldThis week on CMO Confidential, Mike Linton sits down with Dwight Hutchins—Senior Partner & Managing Director at Boston Consulting Group and adjunct professor at Northwestern—to tackle the question every CMO hears from the CFO: “Keep the top line growing… and cut your budget.”Dwight explains how to find waste without hurting performance, where AI actually improves efficiency (and where it doesn't), how to test into cuts with confidence, and why many brands still miss “sufficiency” by spreading spend like peanut butter. We dig into frequency capping, working vs. non-working ratios, zero-based budgeting (used sanely), org design, insource vs. outsource, and a real-world case where a company freed up billions and redeployed it to growth channels. Stay for his “Wild West” in-store marketing story—complete with batteries taped to milk.Sponsored by Typeface — the AI-native, agentic marketing platform that turns one idea into thousands of on-brand assets across channels, safely integrated with your MarTech stack. See how leaders like ASICS and Microsoft scale personalized content with Typeface.⸻⏱️ Chapters00:00 – Intro & guest: Dwight Hutchins (BCG)02:05 – The market reality: uncertainty, shifting buyer values06:10 – CFO pressure: “grow and cut” in the same breath09:20 – AI spend vs. payoff: recalibrating expectations12:25 – Media fragmentation & the “peanut butter” budget problem15:55 – Where AI helps most: measurement, targeting, creative ops19:10 – Forensic cuts case study: freeing up massive dollars23:10 – Finding waste: frequency caps, ad length, quality controls27:05 – “First Fast Response”: demand spaces & brand power30:20 – Sufficiency & focus: stop starving campaigns33:05 – Working vs. non-working: ratios that actually move results35:20 – Zero-based budgeting (in moderation, with data)37:10 – Org & ops: redesigning execution, in/outsourcing lines38:55 – Fun story: the “batteries-on-milk” promo & promo ROI40:00 – Final takeaways & sponsor⸻CMO Confidential, Mike Linton, Dwight Hutchins, Boston Consulting Group, BCG, marketing efficiency, reduce marketing spend, AI in marketing, marketing analytics, media mix optimization, frequency capping, working vs non-working, zero-based budgeting, ZBB, demand spaces, brand strategy, executive leadership, CFO CMO alignment, budget cuts, marketing operations, insource vs outsource, creative operations, measurement and attribution, marketing governance, content at scale, Typeface, Typeface AI, generative AI for marketing, agentic AI, MarTech integration, CMOs, marketing leadership, board expectations, growth and efficiency, case study, social media shift, campaign sufficiencySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode 192 with Lindokuhle Shongwe, Project Leader at BCG and co-author of Africa Unleashed: Harnessing Africa's Critical Mineral Opportunity.Africa sits at the centre of the global energy transition. With vast reserves of cobalt, lithium, copper, platinum group metals and rare earths, the continent holds the minerals powering electric vehicles, clean energy, digital infrastructure and advanced manufacturing.In this episode, Lindokuhle Shongwe of BCG explains how Africa can turn its geological advantage into sovereign, sustainable and scalable growth. He unpacks the findings from the landmark BCG report Africa Unleashed, outlining why critical minerals matter, the continent's leverage in the global mineral race, and the bold choices African leaders must make in this decisive decade.What We Discuss With LindokuhleWhat critical minerals are and why they are central to the 21st century global economyAfrica's unique geological advantage in the global energy and industrial transitionHow the continent can move beyond raw mineral exports to industrial transformation and value chain developmentThree strategic levers to unlock Africa's potential including investment, regional collaboration and global alliancesCase studies from Namibia, Morocco, Rwanda, the DRC and Zambia showcasing best practices in policy, ESG and innovationThe socio economic opportunity including jobs, skills, infrastructure and inclusive growth if Africa captures more value locallyVerto CornerIn this week's Verto Corner, James Booth, Head of Revenue at Verto, explores Africa's fast growing digital economy and the payment challenges holding it back. He explains how businesses such as marketplaces, SaaS platforms and exporters are losing margins to foreign exchange pressures and slow settlements, and why tackling these bottlenecks could unlock the next wave of growth. James also looks at how scalable models can be built in volatile markets and why reducing payout fragmentation is central to driving revenues across the continent.Access the Strategy HandbookDid you miss my previous episode where I discuss The Roads We Never Build: Rethinking Access to Infrastructure Finance in Africa? Make sure to check it out!Connect with Terser:LinkedIn - Terser AdamuInstagram - unlockingafricaTwitter (X) - @TerserAdamuConnect with Lindokuhle:LinkedIn -  Lindokuhle Shongwe and Boston Consulting Group (BCG)Discover how Verto's solutions can help you accept payments, manage expenses, and scale with ease here

What happens when you're suddenly asked to lead the very people who used to be your peers?For Carolynn Smith, that moment came with her first big promotion. It taught her lessons about courage, discomfort, and how leadership often begins by stepping into the unknown.Today, Carolynn is Head of U.S. Service and Enterprise Process Excellence at Prudential Financial. She oversees large-scale transformation efforts and shapes how customer care is delivered at one of the country's leading financial services companies.In this conversation, guest host Karen Lellouche Tordjman sits down with Carolynn to talk about seeking discomfort, the role of AI in reimagining customer experience, and what it really takes to grow into leadership. Along the way, Carolynn reflects on raising a family while rising through the ranks, and why leaning into discomfort has been her best teacher.1:59 Core Values and a Promotion3:13 Business vs. Personal Relationships4:50 Surround Yourself With People Smarter Than You8:18 Seeking Discomfort 10:15 “Work-Life Blend”14:03 AI and Customer Experience17:45 Managing Customer ExpectationsLinks:Carolynn Smith on LinkedInSuchi Srinivasan on LinkedInKamila Rakhimova on LinkedInKaren Lellouche Tordjman on LinkedInAbout In Her Ellement: In Her Ellement highlights the women and allies leading the charge in digital, business, and technology innovation. Through engaging conversations, the podcast explores their journeys—celebrating successes and acknowledging the balance between work and family. Most importantly, it asks: when was the moment you realized you hadn't just arrived—you were truly in your element?About The Hosts:Kamila Rakhimova is a fintech leader whose journey took her from Tajikistan to the U.S., where she built a career on her own terms. Leveraging her English proficiency and international relations expertise, she discovered the power of microfinance and moved to the U.S., eventually leading Amazon's Alexa Fund to support underrepresented founders.Suchi Srinivasan is an expert in AI and digital transformation. Originally from India, her career includes roles at trailblazing organizations like Bell Labs and Microsoft. In 2011, she co-founded the Cleanweb Hackathon, a global initiative driving IT-powered climate solutions with over 10,000 members across 25+ countries. She also advises Women in Cloud, aiming to create $1B in economic opportunities for women entrepreneurs by 2030.Karen Lellouche Tordjman is a Managing Director & Senior Partner at BCG. She has spent over 2 decades in the firm supporting clients across Europe, the US and Latin America. She leads the Customer Experience topic globally for BCG, and is an expert in omnchannel & AI transformation.Subscribe to In Her Ellement on your podcast app of choice to hear meaningful conversations with women in digital, business, and technology.

In a conversation with CancerNetwork® following the FDA approval of the gemcitabine intravesical system (Inlexzo; formerly TAR-200) for patients with high-risk, Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC), Gary Steinberg, MD, discussed how this regulatory decision may impact the treatment paradigm. Steinberg, a professor in the Department of Urology at Rush University, highlighted an unmet need for those with BCG-unresponsive, high-grade NMIBC. With a different mechanism of action compared with prior therapeutic choices in the field, he stated that the gemcitabine intravesical system may allow patients and physicians to benefit tremendously. Based on supporting data from the phase 2 SunRISe-1 trial (NCT04640623), he described how the gemcitabine intravesical system may replace prior standards such as intravesical gemcitabine plus docetaxel. The conversation also touched upon considerations for preventing the risk of progression to metastatic disease with delayed cystectomy, as Steinberg emphasized following up with patients via cystoscopies, urinary cytologies, CT scans, or MRI imaging after treatment with the intravesical system. Steinberg also detailed strategies for mitigating urinary frequency, dysuria, and other toxicities associated with the therapy. He noted a “fine line” regarding bladder medication administration to older patient populations, as these practices may cause adverse effects such as dry mouth, constipation, and blurry vision. Looking ahead, Steinberg illustrated a need to clarify the immunologic effects of regimens like the gemcitabine intravesical system, which can inform the use of additional therapeutic combinations down the road. He highlighted how other novel agents like cretostimogene grenadenorepvec (CG0070) may further improve outcomes in the NMIBC landscape. “One of the key questions that we all need to ask with all our treatments is not about the patients who respond, but about the patients who do not respond,” Steingerg stated regarding the potential next steps for research. “We can begin to understand mechanisms of resistance so that we can target those mechanisms of resistance and treat them better.” Reference U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to transform how certain bladder cancers are treated. News release. Johnson & Johnson. September 9, 2025. Accessed September 22, 2025. https://tinyurl.com/4zjz22z7

Send us a textConsulting recruiting has changed, and digital assessments are now the new gatekeeper. In this episode, we break down what McKinsey, Bain, and BCG's digital tests look like in 2025, what skills they're really testing, and how you can prepare with confidence.Whether you're facing McKinsey Solve, Bain's Gorilla test, or BCG's CCA, this conversation gives you the latest insights and prep tips straight from candidates and firms.Additional Resources:Explore our deep dives into digital assessments across MBB, Big 4, and boutique firmsPremium client or partner student? Take the new Bain Gorilla practice test in your MC accountHelp us keep resources up to date – share your digital assessment experience anonymouslySubscribe to Management Consulted on YouTube for weekly case prep, recruiting insights, and firm updatesPartner Links:Stax is hiring! See open roles and requirementsGet real consulting experience from your bedroom in the November 2025 Strategy Sprint project; $200 off expires October 3 Listen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

In the latest episode of FOX Rehabilitation's Live Better Longer podcast, we shine a spotlight on a remarkable Success. Debra Prox, OTR/L, BCG, NDT, LSVT, CLT, shares the inspiring journey of her patient, Paul, whose life was upended by a debilitating stroke. From Day One, Paul faced significant functional and cognitive challenges, but with Debra's expert guidance—and the steadfast support of his wife, Anita—he began a path toward reclaiming his independence. Hear how Debra strategized, collaborated with FOX clinicians from other disciplines, and tapped into Paul's motivation to build momentum. Small victories along the way turned into lasting progress. This episode highlights the transformative power of therapy, the importance of family involvement, and the emotional reward of witnessing a Success Story being written right in front of your eyes.

In the latest episode of FOX Rehabilitation's Live Better Longer podcast, we shine a spotlight on a remarkable Success. Debra Prox, OTR/L, BCG, NDT, LSVT, CLT, shares the inspiring journey of her patient, Paul, whose life was upended by a debilitating stroke. From Day One, Paul faced significant functional and cognitive challenges, but with Debra's expert guidance—and the steadfast support of his wife, Anita—he began a path toward reclaiming his independence. Hear how Debra strategized, collaborated with FOX clinicians from other disciplines, and tapped into Paul's motivation to build momentum. Small victories along the way turned into lasting progress. This episode highlights the transformative power of therapy, the importance of family involvement, and the emotional reward of witnessing a Success Story being written right in front of your eyes.

In the latest episode of FOX Rehabilitation's Live Better Longer podcast, we shine a spotlight on a remarkable Success. Debra Prox, OTR/L, BCG, NDT, LSVT, CLT, shares the inspiring journey of her patient, Paul, whose life was upended by a debilitating stroke. From Day One, Paul faced significant functional and cognitive challenges, but with Debra's expert guidance—and the steadfast support of his wife, Anita—he began a path toward reclaiming his independence. Hear how Debra strategized, collaborated with FOX clinicians from other disciplines, and tapped into Paul's motivation to build momentum. Small victories along the way turned into lasting progress. This episode highlights the transformative power of therapy, the importance of family involvement, and the emotional reward of witnessing a Success Story being written right in front of your eyes.

AI and data help tell us what people do, but not why. Lauren Taylor, global leader of BCG's Center for Customer Insight, makes sense of the mixed signals that consumers give off. To truly understand what drives people, businesses of course value robust, real-time data. But they also must uncover the context, motivators, and human truth behind every choice. Learn More:Lauren Taylor: https://on.bcg.com/4nfwZ1A BCG's Latest Thinking on Customer Insights: https://on.bcg.com/46iy6Yt The Paradox of Pessimism: Why Gloomy Consumers Keep Spending: https://on.bcg.com/3Ir7FH2 Unpacking the $15 Trillion Opportunity in Leisure Travel: https://on.bcg.com/4gGyCTI Mapping the Consumer Touchpoints That Influence Decisions: https://on.bcg.com/3IBLBcD GenAI's Role in Customer Insights: Think "And" Not "Or": https://www.linkedin.com/pulse/genais-role-customer-insights-think-ajr3c/ Chapters 00:00-01:25 Introduction/Lauren's ‘So What' 01:26-02:39 How can businesses cut through the contradictions and truly understand what customers want? 02:49-03:18 Should we just ignore what people say? 03:19-04:37 What is consumer sentiment? 04:38-05:35 What can businesses really learn from consumers? 05:36-06:20 What factors play into the say-do gap? 06:21-07:45 How much does emotion shape what people buy? 07:46-09:08 How and why should businesses deaverage the customer? 09:09-10:17: How nuanced is motivation across different regions? 10:18-12:10 What parts of the customer journey actually shape what people choose? 12:11-12:52 Has AI helped us better understand customers or made things more confusing? 12:53-13:51 How can companies make sense of conflicting signals? 13:52-14:46 How is AI changing the way that we understand consumer behavior? 14:47-16:19 With data available, why is it critical for businesses to still talk to customers? 16:20-17:07 What mistakes are companies making when it comes to listening to their customers? 17:08-17:32 What should companies look for in sentiment signals? 17:33-18:04 Lauren's ‘Now What' 18:05-18:27 Do milestone moments matter? 18:28-18:42 Outro This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

From the archive: This episode was originally recorded and published in 2022. Our interviews on Entrepreneurs On Fire are meant to be evergreen, and we do our best to confirm that all offers and URL's in these archive episodes are still relevant. Robert Huntington is CEO of Metric Collective, a vertically integrated franchise and technology company. Before Metric he was a BCG consultant, teacher, 50M dollars P and L manager and franchise executive. Top 3 Value Bombs 1. Once you've already proven that you can execute the model, that's when you can start innovating the model. 2. If you have good union economics - if you have something that customers need - and the market is growing, then franchising can be a really attractive route. 3. Franchising means you're in business for yourself - not by yourself. Fill out the lead form and let's chat about franchising - Metric Collective Sponsors HighLevel - The ultimate all-in-one platform for entrepreneurs, marketers, coaches, and agencies. Learn more at HighLevelFire.com. Gelt - Your year-round tax partner built for entrepreneurs, business owners, investors, and high net-worth individuals who want to keep more of what they earn. Get a personalized consultation and 10 percent off your first year when you mention Entrepreneurs on Fire. Visit JoinGelt.com/eof. Public - Build a multi-asset portfolio of stocks, bonds, options, crypto, and more. Go to Public.com/fire to fund your account in five minutes or less. All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Public Investing, Inc., member FINRA and SIPC. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank. Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1890144), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. Alpha is an experimental AI tool powered by GPT-4. Its output may be inaccurate and is not investment advice. Public makes no guarantees about its accuracy or reliability - verify independently before use. Rate as of 6/24/25. APY is variable and subject to change. Terms and Conditions apply.

Willkommen zur neuen Folge von Choose Germany – dem Business-Punk-Podcast für alle, die dieses Land nicht schlechtreden, sondern neu gestalten wollen. In Partnerschaft mit dem Startup-Verband und powered by BCG holen wir Deutschlands mutigste Macher:innen ans Mikro.Zu Gast: Heike Freund, COO von Marvel Fusion (München). Heike arbeitet an nichts Geringerem als der Kommerzialisierung der Fusionsenergie – saubere, sichere, CO₂-freie Energie, ausgelöst durch Hochleistungslaser und winzige Treibstoffkügelchen. Wir sprechen über die große Finanzierungsrunde, die neue Experimentalkammer in München und die Frage, wie Deutschland vom Deeptech-Standort zum Kraftwerksbauer wird.Worüber wir sprechen:⚡ Fusion explained: Warum Laser-getriebene Fusion der potenzielle Gamechanger für den Energiemix ist – und was Marvel Fusion dafür baut.

From the soccer field to the consulting world — Luis's journey is nothing short of inspiring. In this video, he shares how he went from being a student-athlete at Colby College to landing an Associate role at BCG. You'll hear about his recruiting struggles, networking strategies, case interview prep, and the key lessons that helped him turn rejections into offers. If you're a student, athlete, or aspiring consultant, this story will give you the motivation and practical insights to break into top consulting firms like BCG, McKinsey, and Bain. Colby College, BCG Associate, student athlete consulting, how to get into BCG, breaking into consulting, consulting recruiting journey, case interview prep, networking for consulting, MBB consulting success story, management consulting career tips.

In this episode of Better Edge, Joshua Meeks, MD, PhD, discusses the implications of the FDA's recent approval of TAR-200, a novel therapy for bladder cancer. Having played a key role in the clinical trials and development of this treatment, Dr. Meeks provides an in-depth look at this breakthrough's potential to transform patient care, especially for those with BCG-unresponsive bladder cancer.

IMPACT OF AI IN THE BLUE CHIP GRADUATE CAREER   In the before times, the passport to comfortable middle class prosperity was go to a good University, get a 2.1 or above, and apply to a graduate scheme with a blue chip organisation. Most attractive were the global professional services firms - McKinsey, Accenture, PwC, KPMG, BCG and the rest. With the advent of AI replacing a great deal of the knowledge related tasks previously performed by graduate entry into these firms, is this path no longer as viable as it once was?     Lets deep dive:   - State of the blue chip graduate recruiting market - What is the volume of intake 2020-2025? - What type of work might we have expected from early entry employees in PS? - How much of this is 'exposed' to AI disintermediation? - Does AI have a different impact rather than direct replacing the task? - What do PS firms expect from early entry talent in 2025 and beyond? - How can early entry talent best position for a future in PS? - How will Management Consultancy itself change over time?   All this and more, with Yazad Dalal, Chief Growth Officer (Joveo), Marketa Simkova, Partner, Head of People, Performance, Culture - KPMG Middle East & Sophie Jablansky, Senior PM (Veris Insights)from within the Professional Services and Management Consultancy sector.   We are on Friday 12th Sep, 2pm BST - follow the channel here (recommended) and save your spot for this demo by clicking on the green button.     Ep329 is sponsored by our friends Joveo   As the global leader in AI-powered recruitment marketing and candidate engagement, we are transforming talent attraction and recruitment media buying for the world's largest and smartest employers, staffing businesses, RPOs, and recruitment advertising agencies.   Want to find out more?   Speak to one of our team today.

M&A activity is waking up, but many companies are reluctant to leap into the fray. Daniel Friedman, BCG's global leader of transactions and integrations, explains why bold moves now could pay off. Waiting may feel safe, but the cost could be forfeiting once-in-a-decade opportunities. Learn More: Daniel Friedman: https://on.bcg.com/4mWHyGW Mid-2025 M&A Insights: https://on.bcg.com/3V6ENGF BCG's Latest Thinking on M&A: https://on.bcg.com/4ndP9QU BCG's M&A Sentiment Index: https://on.bcg.com/3VEdBzb 00:00-02:56 Intro/Daniel's ‘So What' 02:57-04:34 What is different now vs. the beginning of the year? 04:35-06:13 How quickly will the market recover? 06:14-08:20 What regions and sectors are particularly active? 08:21-09:01What are risks that could impede recovery? 09:02-10:26 What is wrong with waiting on the sidelines? 10:27-12:00 Do downturn deals tend to deliver more value than boom time deals? 12:01-13:25 What can a company to do ensure that it finds the right deal? 13:26-17:02 How has M&A changed in a more uncertain world? 17:03-18:03 How will AI evolve? 18:04-19:45 What are the winners doing right in this new environment? 19:46-21:16 The ‘Now What' 21:17-21:33 OutroThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us a textWant to land a consulting role in Canada? This episode walks you through everything you need to know about breaking into consulting in 2025.We cover:The current Canadian consulting market and how it differs from the U.S. and U.K.3 recruiting power moves you can apply immediatelyKey target schools, top firms, and the hiring timeline2025 salary preview across McKinsey, Bain, BCG, and moreFor the complete playbook, download Management Consulted's 2025 Canada Recruitment Roadmap – free. It's packed with firm-by-firm insights, deadlines, and strategies to help you land an offer in Toronto, Montreal, Vancouver, or Calgary.Additional Resources:Review 2025 Canada consulting application deadlinesJoin Black Belt, an expert prep program that's helped hundreds land offers in CanadaPartner Links:Stax is hiring! See open roles and requirementsListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

As one of the world's great technology companies, Siemens needs no introduction, but is notable for not only a holistic approach to sustainability but, in particular, for the way sustainability has been integrated into the heart of the business model. But how do they drive the sustainability agenda with more than 300,000 people? How do they innovate at such a scale? How do they bring technology and sustainability together in practice? And how are their efforts received by their customers, employees, and investors?We are delighted to be joined by Dr. Eva Riesenhuber, the Global Head of Sustainability at Siemens, to help share insights into these questions and more. Eva started her career as a lawyer, with a doctorate in international public law and more than a decade of experience as a finance lawyer in New York. From there, Eva has worked as an SVP in the Siemens M&A department, as CFO of Next47, the Siemens-owned venture capital firm, and as the Head of Investor Relations at Siemens. She became Global Head of Sustainability in October 2022 and is a member of the supervisory board of Siemens Mobility GmbH.Building on her strong foundations in law and value creation, Eva speaks with Vincent Chin, Managing Director & Senior Partner at BCG and Asia Pacific Regional Leader of the BCG Henderson Institute, about the role of innovation, the people agenda, and the shareholder perspective in Siemens' sustainability efforts. They cover decarbonizing in conjunction with customers, building new approaches to product design, ensuring that efforts are globally inclusive, and the role of AI. Eva's unique viewpoints make this essential listening for those looking to activate large organizations to deliver a competitive advantage through sustainability.

Willkommen zur neuen Folge von Choose Germany – dem Business-Punk-Podcast für alle, die dieses Land nicht schlechtreden, sondern neu gestalten wollen. In Partnerschaft mit dem Startup-Verband und powered by BCG holen wir Deutschlands mutigste Macher:innen ans Mikro.Zu Gast: Fabian Kienbaum – Unternehmer und People-Leadership-Experte. Mit Carsten spricht er darüber, warum Deutschland sofort Tempo aufnehmen muss: weniger Bürokratie, wettbewerbsfähige Energie- und Steuerrahmen, schnellere Visa – und vor allem ein klares Zielbild: Lust auf Zukunft.Fabian ordnet ein, warum wir „mit dem Rücken zur Wand“ stehen, was ein Regulierungs-Moratorium bringen könnte und wieso Wettbewerbsfähigkeit zur Top-Priorität der Politik werden muss. Er erklärt, wie qualifizierte Zuwanderung praktisch scheitert – von IHK-Schleifen bis zähen Visa – und was es braucht, um Talente wirklich willkommen zu heißen.Beim Thema Kapital plädiert er für europäisches Denken: Kapitalströme harmonisieren, institutionelles Geld in Innovation bringen – und positive Signale (z. B. Stiftungsvermögen in VC) skalieren. Planungssicherheit statt Fragmentierung.Sein Appell an Unternehmen: HR als Business-Accelerator denken. Sichtbarkeit schaffen, Dialogfähigkeit aufbauen, Personal- und Employer-Branding verzahnen – denn Menschen folgen Menschen, und Selbstwirksamkeit stiftet Motivation.Und: KI & Bildung. Deutschland muss leapfroggen – Technologie in Verwaltung und Mittelstand radikal anwenden und das Bildungssystem auf Anwendungskompetenz ausrichten. Nur so bleibt „Made in Germany“ mehr als ein Etikett – eine Story, die wieder Talente und Investitionen anzieht.Es geht um:

Do you avoid conflict—or use it to grow your influence? In this episode, AJ and Johnny share a science-backed framework for conflict resolution that transforms tense moments into opportunities for trust and leadership. Drawing on John Gottman's research on relationships and Google's Project Aristotle findings on high-performing teams, they reveal why conflict isn't a problem to eliminate—it's a chance to deepen respect and build long-term influence. You'll learn a step-by-step system to handle everyday workplace and relationship conflicts without burning bridges: lead with value, accept responsibility, show empathy, and present solutions that create buy-in. With stories from clients like Marcus, a consultant at BCG, AJ and Johnny show how mastering conflict resolution can make you the person others turn to when stakes are high. If you've ever felt conflict-averse, this episode gives you practical tools to stay calm, confident, and in control. What to Listen For [00:00:00] Why avoiding conflict costs you influence [00:00:56] How conflict avoidance limits your “career chessboard” moves [00:01:27] The science of conflict: shifting from “me vs. you” to “us vs. the problem” [00:02:43] The High-Value Conflict Framework explained [00:03:28] Step 1: Lead with value to disarm defensiveness [00:03:54] Step 2: Accept responsibility without weakness [00:06:23] Step 3: Use empathy and “we” language to build trust [00:07:26] Step 4: Present options, not ultimatums [00:09:18] Why well-resolved conflicts create stronger bonds [00:11:03] Client story: how Marcus became the go-to conflict solver [00:11:29] Why mastering conflict is the ticket to influence A Word From Our Sponsors Stop being over looked and unlock your X-Factor today at ⁠unlockyourxfactor.com⁠  The very qualities that make you exceptional in your field are working against you socially.  Visit the ⁠artofcharm.com/intel ⁠for a social intelligence assessment and discover exactly what's holding you back. Indulge in affordable luxury with Quince. Upgrade your wardrobe today at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠quince.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for free shipping and hassle-free returns. Grow your way - with Headway! Get started at ⁠makeheadway.com/CHARM ⁠and use my code CHARM for 25% off. Ready to turn your business idea into reality? Sign up for your $1/month trial at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Need to hire top talent—fast? Claim your $75 Sponsored Job Credit now at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Indeed.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. This year, skip breaking a sweat AND breaking the bank. Get your summer savings and shop premium wireless plans at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠mintmobile.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Save more than fifty percent on term life insurance at ⁠SELECTQUOTE.COM/CHARM⁠ TODAY to get started  Curious about your influence level?  Get your Influence Index Score today! Take this 60-second quiz to find out how your influence stacks up against top performers at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠theartofcharm.com/influence⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check in with AJ and Johnny! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AJ on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Johnny on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AJ on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Johnny on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on TikTok⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

What if the real secret to exceptional leadership isn't control, charisma, or even performance—but generosity? Could the “soft stuff” like listening, empathy, and vulnerability truly drive the hardest results in business? In this episode of the Delighted Customers podcast, I dig into that very question with Joe Davis, legendary former Senior Partner at Boston Consulting Group, co-founder of BCG's Washington D.C. office, and author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain”. Joe shares his own journey from traditional, results-driven leadership to a generous, people-centered model—and why unlocking your team's full human potential just might be the most powerful business move you can make. We explore how the traits of generosity drive not only team happiness and loyalty, but also real bottom-line outcomes, making this conversation essential listening for leaders and aspiring leaders at every level. Why should you tune in to this episode? Joe has four decades of hands-on experience innovating in both the private and public sectors, founding major business initiatives within BCG, and working closely with Fortune 500 C-suite leaders. He distills this wisdom into practical strategies—whether you're leading a team of three or a global enterprise of 100,000. His stories from the front lines of consulting, combined with actionable steps for building trust and humanity in the workplace, will change the way you think about leadership forever. Here are three compelling questions Joe answers on the show: Why should organizations and their C-suite invest in “generous leadership” when they're held accountable for hard business outcomes, not just a healthy culture? What are the seven key traits that separate good leaders from exceptional, generous leaders—and how do they play out in real-world scenarios? How can listening, vulnerability, and small acts of recognition dramatically improve your team's performance and engagement? Listen now and subscribe to the Delighted Customers podcast on Apple Podcasts and Spotify! You'll find this episode—and every episode—on all your favorite podcast platforms. If you find value in these conversations, please leave a review and share with a friend or colleague who wants to rethink what great leadership really looks like. Meet Joe Davis Joe Davis is a veteran senior partner at Boston Consulting Group (BCG), where he spent 37 years shaping strategy, developing talent, and transforming organizations at the highest level. Joe co-founded BCG's Washington D.C. office and launched the firm's North American Public Sector business, as well as leading BCG North America. Passionate about advancing equity and inclusion, he also founded and chaired BCG's Center for Inclusion and Equity. Joe is a Harvard Business School graduate and has been at the forefront of helping organizations evolve from top-down, authoritarian structures to cultures of trust, inclusion, and generosity. His experience spans advising CEOs of major corporations to hands-on coaching with emerging leaders. He is the author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain,” a groundbreaking book that reimagines the connection between caring leadership and delivering results. Joe is currently an advisor and coach to BCG's rising partners, teaching them how to inspire, motivate, and build lasting client relationships. You can reach Joe and learn more about his work via his LinkedIn profile or his website at joedavis.com. Show References and Resources “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain” by Joe Davis Amazon Link Joe Davis on LinkedIn: https://www.linkedin.com/in/joe-davis-bcg/ Joe's personal website: https://joedavis.com Harvard Business School: https://www.hbs.edu Boston Consulting Group (BCG): https://www.bcg.com Michigan State University's Trust and Leadership Education: https://broad.msu.edu CEO Joaquin Duato, Johnson & Johnson: https://www.jnj.com/leadership/joaquin-duato Scott Kirby, CEO of United Airlines: https://www.united.com/ual/en/us/fly/company/about/leadership.html Sheila Bair, former FDIC chair: https://www.fdic.gov/about/leadership/sheila-bair/ Thank you for listening to the Delighted Customers podcast!

Becirovic, CIO at Boston Consulting Group, sat down with senior editor Lucas Mearian at Foundry's CIO 100 event to discuss BCG's AI strategy, which emphasizes internal proof-of-concept before external application and focuses on journey-led and experience-led platforms. Becirovic also highlighted the importance of data strategy, upskilling, and managing AI costs effectively. Featuring Merim Becirovic: https://www.linkedin.com/in/merimb/ Lucas Mearian: https://www.linkedin.com/in/lucasmearian/

Warren Zenna sits down with Amy Hsuan, Chief Customer & Revenue Officer at Mixpanel, to unpack what a truly unified revenue engine looks like. Amy shares how org design must follow strategy, why GTM is a core differentiator, and how aligning marketing, sales, success, and services creates consistent end‑to‑end customer experiences that actually win.Amy traces her path from journalism to BCG to Mixpanel, revealing how curiosity, cross‑functional leadership, and a customer‑first mindset shaped her Chief Customer & Revenue Officer role. She explains the shift from “hard” product differentiation to human‑driven trust, and how relationships, not features, become defensible moats in crowded markets.They dig into practical playbooks: orchestrating handoffs, clarifying tone across touchpoints, and reducing executive silos to move faster. Amy outlines a strategy‑to‑execution flywheel, her 80/20 time model for long‑ vs short‑term, and how consistent advisory through complex, multi‑stakeholder cycles sustains momentum and predictability.Amy also shares a grounded view on AI: use it to accelerate research, analysis, and context so leaders increase decision velocity—while humans own listening, rapport, creative adaptation, and navigating org dynamics. If you're a CRO, aspiring CRO, or CEO aiming to modernize revenue leadership, this conversation is a blueprint.

Nos vemos en Summit Regias el 5 de septiembre en el nuevo Hotel Intercontinental. Asegura tu entrada aquí: ⁠⁠https://www.summitregias.comUna niña regia con veintitantos primos y domingos en casa de la abuela. Una joven que zigzagueó entre diplomacia, banca, consultoría y startups, hasta que el cierre inesperado de la empresa en la que trabajaba le mostró una puerta que no pensaba abrir: la de fundar. ¡Y en Silicon Valley!Su empresa de biotecnología nació con una presentación de 12 filminas, tres socios improbables y un cheque inicial. Hoy los millones de dólares de inversión se han multiplicado, y también el número de patentes y las alianzas globales.Vive con su marido y tres hijos lejos de México, pero no del idioma español; ni de las arepas venezolanas aportadas por el papá o el altar de Muertos promovido por la mamá. De su abuelo aprendió que la iniciativa es importante, pero es más importante la terminativa. Y eso, en su historia, no es una sola frase: ha sido la diferencia entre imaginar y lograr.Acerca de Sofía: Es cofundadora y presidenta de Brightseed, donde lidera el desarrollo de soluciones con inteligencia artificial para descubrir moléculas bioactivas con aplicaciones nutricionales y terapéuticas.Antes impulsó la comercialización de proteínas vegetales innovadoras y trabajó en BCG, donde fue miembro fundadora del BCG Henderson Institute. También ha sido asesora especial de la ONU en colaboración con el sector privado.Es licenciada en Filosofía, Política y Economía por la Universidad de Pensilvania y tiene un MBA por Stanford. Ha sido reconocida como Young Global Leader por el Foro Económico Mundial y ha participado como ponente en foros internacionales de nutrición, IA y asuntos globales.

Starboard is building AI-first infrastructure to transform global trade by improving the productivity of freight forwarders—the central coordinators who connect 15-20 different parties in every international trade transaction. With 15 years of experience in the industry, including roles at Maersk, BCG, and Flexport, Sumeet Trehan saw an opportunity to modernize an industry that has invested heavily in physical infrastructure but neglected technological innovation. The company has raised $5.5 million and is approaching $1 million ARR while creating an entirely new category they call "AI-first forwarders." Topics Discussed: Building AI infrastructure to automate freight forwarding coordination and quoting processes Creating a new category in the traditional, relationship-driven logistics industry Go-to-market strategies for selling to an "old boys club" industry that operates differently from typical SaaS markets The founder's decision to personally handle the first 20-30 sales before hiring any sales staff Vision for transforming global trade by creating a comprehensive platform for small-to-mid-sized importers   GTM Lessons For B2B Founders: Cold calling still works in traditional industries: Starboard generates significant top-of-funnel activity through direct cold calling, with freight forwarders actually appreciating the personal touch. Sumeet's team achieves a 10% pickup rate and converts 15-20% of answered calls to discovery meetings by being upfront about the cold call nature and immediately focusing on business outcomes. The approach works because their target market—freight forwarders—are accustomed to making and receiving cold calls as part of their daily business operations. Door-to-door prospecting remains viable for relationship-driven markets: In industries where personal relationships dominate, physical presence can be a differentiator. Starboard literally brings donuts to prospects' offices, which works because their target market values face-to-face interactions. This approach only makes sense when your industry culture supports it and when the lifetime value of customers justifies the time investment. Founders should personally execute early sales to understand the playbook: Rather than immediately hiring sales staff after raising funding, Sumeet chose to personally close the first 20-30 deals. This allowed him to deeply understand customer pain points, refine the sales process, and develop a replicable methodology before bringing on sales team members. Only after proving out the top-of-funnel motion did he hire his first SDR, and only after closing 15-20 deals did he hire a sales leader. Physical implementation presence drives early-stage product adoption: For complex B2B products still achieving product-market fit, being physically present during implementation creates stronger relationships and better feedback loops. Starboard's team travels to be on-site when clients first use the product, which helps with both adoption rates and product development insights. They maintain ongoing communication through WhatsApp and Teams channels rather than Slack, adapting to their customers' preferred communication methods. Category creation requires education over product promotion: Starboard's marketing strategy focuses entirely on educating the market about AI's potential impact on logistics rather than promoting their specific product. By speaking at events, writing blogs, and participating in podcasts about industry transformation rather than Starboard features, they position themselves as thought leaders. This approach builds trust and creates demand for the category before potential customers are ready to evaluate specific solutions. Sequencing product development based on customer feedback: The company's current quoting product serves as a wedge, with plans to expand into marketplace functionality and then full operations automation. Each expansion builds on customer relationships and data from the previous phase. This measured approach to product development ensures each step creates value while building toward the larger vision of comprehensive trade infrastructure.   //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.  www.GlobalTalent.co   //   Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM 

How do law firms really decide what partners get paid?Partner compensation is one of the most important and controversial topics in the legal industry. The way firms structure pay doesn't just impact income; it shapes firm culture, collaboration, and long-term profitability.In this episode of Financially Legal, Emery Wager sits down with Hugh Simons (former BCG consultant, law firm CEO, and prolific writer on law firm economics) to unpack:The major compensation models (lockstep, points-based, and eat-what-you-kill)Why open vs. closed pay systems matter more than you thinkHow incentives drive collaboration, culture, and firm growthWhere partner compensation is headed in the next decadeWhether you're a managing partner, CFO, or simply curious how partner pay really works, this episode pulls back the curtain on a system that defines the legal industry.

Transformation isn't a gamble—it's science. Kristy Ellmer, a leader with BCG Transform, unpacks the research behind what really makes change work: involving employees in the journey, preparing for the “messy middle,” and building emotional and practical support into the process. Successful efforts focus equally on shifting behaviors and mindsets, not just strategy and structure. Learn More: Kristy Ellmer: https://www.bcg.com/about/people/experts/kristy-ellmer BCG's Latest Thinking on Business Transformation: https://www.bcg.com/capabilities/business-transformation/insights To Keep Transformations on Track, Incentives Are Crucial: https://www.bcg.com/publications/2025/incentives-are-crucial-for-transformation-success The Transformation Paradox: How to Grow When the Growing Gets Tough: https://www.bcg.com/publications/2025/transformation-paradox-how-grow-when-growing-gets-tough This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us a textGetting invited to a second round consulting interview is a huge achievement, but it's not the finish line. The final round is where the offer is won or lost. In this episode, Jenny Rae shares exactly how to prepare for 2nd-round consulting interviews, including advanced case interview strategies and fit interview best practices. Whether you're interviewing with McKinsey, Bain, BCG, or another top consulting firm, this guide will help you turn your second-round invite into a full-time offer.Additional Resources:Start your Case Prep Plan (free!)Black Belt Case Prep Program: Your one-stop shop for case + fit interview prep, from round 1 to the offerYouTube playlist of Case Interview ExamplesStay on top of Consulting Application DeadlinesListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Send us a textStep inside a live McKinsey-style case interview. In this episode, former McKinsey consultant and expert coach Mark Di Giorgio leads a candidate through a market entry case set in the nutrition and healthcare industry.Watch how the case unfolds, including:Structuring a US market entry problemSizing the diabetes supplement marketEvaluating retail vs. direct sales channelsAssessing risks and competitor responsesIf you're preparing for McKinsey, BCG, or Bain, this is your chance to experience the pressure of a real interview and learn how to communicate with structure, clarity, and confidence.Want personalized feedback and practice with Mark? Book a one-on-one coaching session today below. Spots fill quickly.Work with Mark:See Mark's current coaching availabilityPurchase the Black Belt case prep program for 1:1 coaching with Mark Connect on LinkedInPartner Links:Stax is hiring! See open roles and requirementsListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Is AI coming for your job? Boston Consulting Group's Global Lead for People and Organization, David Martin, reveals the truth about workforce disruption, survival strategies, reskilling, and the future of work.With only 20% of employees effectively using AI tools despite 80% expressing excitement, discover why adoption is failing and what leaders must do differently.

A CMO Confidential Interview with David Aaker, Vice Chair of Prophet, author of numerous marketing books including Aaker on Branding 2nd Edition, formerly a Haas School of Business Professor. David discusses the history of brand equity starting with the BCG model from the 90's and why that model and scanner data drove a short-term sales focus at the expense of brand equity. After years of progress, he believes we are now experiencing "A revival of short-termism." Key topics include: the differences between B2B and B2C brand building; the need for marketers to appreciate that brands aren't built in isolation; and how to break through in a hostile communications environment. Tune in to hear why he believes "There are easy ways for companies to build better brands," and case studies from Dove and Uniqlo. Brand value has been discussed for decades—so why isn't it a universally accepted business principle? In this episode of CMO Confidential, host Mike Linton sits down with branding legend David Aaker, Vice Chair at Prophet, author of 18 books, and widely regarded as the “Father of Modern Branding,” to unpack why the fight for brand equity is far from over.From the origins of brand equity in the 1990s to today's hostile marketing environment, Aaker shares insights on: • Why brand should be treated as a long-term asset, not a short-term tactic • How short-termism and performance marketing are eroding brand value • The difference between B2B and B2C brand management (and why organizational values matter more in B2B) • Examples of brands that have nailed disruptive innovation and purpose-driven branding (Dove, Uniqlo, Habitat for Humanity) • Why most companies are managing brands poorly in today's cluttered, skeptical media environment • How AI could democratize creativity and make professional branding accessible to more companiesPacked with history, frameworks, and practical examples, this conversation will change the way you think about brand value, brand portfolios, and how to make your brand truly indispensable.00:00 – Introduction to CMO Confidential & Guest David Aaker01:15 – Why Brand Value Still Isn't a Universally Accepted Principle03:45 – The Birth of Brand Equity in the 1990s06:10 – Short-Termism, Performance Marketing, and the Brand Erosion Problem08:35 – How to Justify Brand as an Asset (Case Studies & Examples)11:20 – The Visibility Advantage and 14 Dimensions of Brand Value13:05 – Why CFOs and Boards Believe in Other Brands, but Not Their Own15:10 – B2B vs B2C Branding: Key Differences and What Matters Most17:45 – Why Many Companies Are Managing Brands Poorly Today20:00 – Branding in a Hostile Communication Environment22:05 – The Power of Brand Portfolios, Companion Brands, and “Silver Bullet” Brands24:30 – Examples: Uniqlo, HeatTech, and the Westin Heavenly Bed26:10 – Super Bowl Advertising: Breaking Through Clutter and Skepticism28:00 – AI, the Democratization of Creativity, and the Future of Branding29:20 – Final Advice: Your Duty as a Marketer to Build the Brand as an Asset30:15 – Closing Remarks & SubscribeHere's your list fully hashtagged and comma-separated:#cmoconfidential, #DavidAaker, #brandvalue, #brandequity, #brandstrategy, #marketingstrategy, #brandingadvice, #B2Bbranding, #B2Cbranding, #brandmanagement, #shorttermism, #performancemarketing, #purposedrivenbranding, #DoveRealBeauty, #UniqloHeatTech, #HabitatforHumanity, #marketingleadership, #brandportfolio, #brandeddifferentiators, #brandedenergizers, #brandedsourceofcredibility, #hostilemediaenvironment, #disruptiveinnovation, #AIinbranding, #democratizationofcreativity, #CMOpodcast, #marketingpodcastSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

曾經高舉人道主義理想的以色列，如今在加薩走廊犯下的戰爭罪行，究竟是正義反擊，還是失控的種族清洗？ 《經濟學人》嚴厲指出，以色列將一開始正義的戰爭，演變成無止盡的死亡與破壞。加薩走廊大部分地區淪為廢墟，數百萬平民流離失所，而納坦雅胡政府甚至將糧食援助武器化，導致飢荒與死亡蔓延。更諷刺的是，哈馬斯早已被削弱，不足以對以色列構成威脅，這場戰爭已失去戰略意義。 哈瑪斯的罪行並不能為以色列開脫，作為一個民主國家。以色列應該用遠高於恐怖分子、軍閥和獨裁者的標準要求自己，關鍵在於以色列是否同意盡快停火、向加薩輸送充足物資，並在戰後成立真正獨立的調查委員會，否則這個誕生於1948年的理想國度，終將黯然失色。 主持人：天下雜誌資深主筆 黃亦筠 主講人：金庫資本管理合夥人兼總經理 丁學文 製作團隊：莊志偉、樂祈、邱宇豪 ＊延伸閱讀｜裁5千人、推1萬名「AI代理」，AI如何衝擊麥肯錫？：https://lihi.cc/142bT ＊立即收聽《天下學習Podcast》：https://hi.cw.com.tw/u/j7jy5LE/ ＊訂閱天下全閱讀：https://bit.ly/3STpEpV ＊意見信箱：bill@cw.com.tw -- Hosting provided by SoundOn

I had a blast sitting down with Dan Schaefer, Founder & CEO of Native Pet.  We kicked things off with gratitude. Dan shared how his wife was his “first angel investor,” backing his leap from BCG into entrepreneurship while raising a young family. From there, we got into the big idea behind Native Pet: “around-the-bowl nutrition.” Instead of trying to replace what's in your dog's bowl, Native Pet helps pet parents customize it with clean-label, effective supplements dogs actually love to eat. Dan walked me through their earliest wins, such as transforming messy canned pumpkin into a shelf-stable powdered pumpkin with a smart fiber blend, and their breakout hit, The Daily (an all-in-one scoop inspired by human greens routines). We also dug into hard-earned lessons (hello, Target packaging panic) and a huge upcoming launch that brings today's human gut-health wave into pet wellness. Highlights * Gratitude that fuels the journey: Dan credits his wife and co-founder Pat's family for believing early, packing boxes, cheering them on, and making “zero to one” possible.   * The Native Pet thesis: Focus on supplements to personalize health “around the bowl,” so pet parents can keep their preferred food and add targeted support.   * Simple, smart innovation: From powdered Pumpkin to Omega Oil, clean-label formats and taste are non-negotiable—if dogs won't eat it, nothing else matters.   * Breakout product: The Daily—their one-scoop daily multivitamin—became Native Pet's best seller and even hit #1 in multivitamins on Amazon right after Prime Day.   * Where to find them: Online at nativepet.com, Amazon, Chewy, and nationwide at Target, Petco, PetSmart, Whole Foods, Sprouts, Tractor Supply, Meijer, Pet Supplies Plus, and more.  Plus, try the website quiz to get the right plan for your dog.   * One more thing I'm excited about: Native Pet's new GutWell line (launching August) targets specific outcomes through the microbiome—Clean Breath, Trim Down, Stress Support, Itchy Skin, and Power Poop—in a tasty, clean-label, cold-pressed pellet with bold, premium packaging. Join me, Ramon Vela, in listening to the episode: If you care about helping your dog live a happier, healthier, and longer life—and want practical ways to personalize their nutrition—you'll love this conversation. Hit play to hear the full story, the lessons learned, and what's next for Native Pet.   For more on Native Pet, visit: https://nativepet.com/ If you enjoyed this episode, please leave The Story of a Brand Show a rating and review.  Plus, don't forget to follow us on Apple and Spotify.  Your support helps us bring you more content like this! * Today's Sponsors:   Saral - The Influencer OS: https://www.getsaral.com/demo SARAL is the all-in-one influencer platform that finds brand-aligned creators, automates outreach, and manages everything in one place. Request a live demo today. Let the SARAL team know you're a The Story of a Brand Show podcast listener to get an extended free trial! Visit the link above. 

How do you effectively treat your bladder cancer population with an insufficient supply of BCG? Dr. Amy Luckenbaugh, a urologic oncologist at Vanderbilt University Medical Center, joins host Dr. Ruchika Talwar to highlight challenges and solutions to managing bladder cancer amidst ongoing BCG shortages. --- This podcast is supported by an educational grant from UroGen Pharma. --- SYNPOSIS Dr. Luckenbaugh and Dr. Talwar delve into the history and significance of BCG in bladder cancer treatment, exploring the reasons behind the shortages and discussing various coping strategies, including split dosing and alternative intravesical therapies like gemcitabine, docetaxel, and the new mitomycin hydrogel. The conversation also covers emerging treatments for high-risk patients, the role of radical cystectomy, and the importance of standardization and innovation in dealing with medication shortages. Dr. Luckenbaugh highlights the importance of patient quality of life, cost considerations, and the need for resilient pharmaceutical supply chains. --- TIMESTAMPS 00:00 - Introduction01:56 - History and Importance of BCG in Bladder Cancer03:21 - Challenges and Shortages of BCG06:36 - Managing BCG Shortages in Clinical Practice12:33 - New Alternatives and Treatments for Bladder Cancer23:28 - The Role of Cystectomy in Bladder Cancer Treatment26:12 - Future Directions and Final Thoughts --- RESOURCES BCG Shortage AUA Recommendations:https://www.auanet.org/about-us/bcg-shortage-info Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre: https://pmc.ncbi.nlm.nih.gov/articles/PMC11951178/ Bladder Cancer Advocacy Network (BCAN):https://bcan.org/ Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)https://pubmed.ncbi.nlm.nih.gov/39446087/b FDA Approves Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle TAR-200 - SunRISe-3 Study:https://www.jnjmedicalconnect.com/products/tar-200/medical-content/tar-200-sunrise-3-study First results from TAR-200 - SunRISe-1 Study:https://www.jnj.com/media-center/press-releases/johnson-johnsons-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibcN-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review:https://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/

Private equity is under pressure to deliver returns in a tougher environment. Clark O'Niell, BCG's global lead for AI infrastructure and cyber in the private investors & private equity practice, shares how the smartest investors are using AI to move beyond hype, drive impact at scale, and future-proof their portfolios. It's about focus over fragmentation—and combining judgment with new tools. Learn More: Clark O'Niell: https://on.bcg.com/46tTmep BCG's Latest Thinking on Private Equity: https://on.bcg.com/4598Fa5 IT Spending Pulse: AI Agents and GenAI Reshape Priorities: https://on.bcg.com/4mmjVXG The So What from BCG on YouTube: https://www.youtube.com/playlist?list=PLMJgyXjV5gMI9JV-GcF_D1Y6zyf1Eab_0This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp